Plasmodium falciparum : new molecular targets with potential for antimalarial drug development

Donald L. Gardiner; Tina S. Skinner-Adams; Christopher L. Brown; Katherine T. Andrews; Colin M. Stack; James S. McCarthy; John P. Dalton; Katharine R. Trenholme

doi:10.1586/ERI.09.93

Plasmodium falciparum : new molecular targets with potential for antimalarial drug development

Donald L. Gardiner, Tina S. Skinner-Adams, Christopher L. Brown, Katherine T. Andrews, Colin M. Stack, James S. McCarthy, John P. Dalton, Katharine R. Trenholme

School of Science

Research output: Contribution to journal › Article › peer-review

35 Citations (Scopus)

Abstract

Malaria remains one of the world's most devastating infectious diseases. Drug resistance to all classes of antimalarial agents has now been observed, highlighting the need for new agents that act against novel parasite targets. The complete sequencing of the Plasmodium falciparum genome has allowed the identification of new molecular targets within the parasite that may be amenable to chemotherapeutic intervention. In this review, we investigate four possible targets for the future development of new classes of antimalarial agents. These targets include histone deacetylase, the aspartic proteases or plasmepsins, aminopeptidases and the purine salvage enzyme hypoxanthine-xanthine-guanine phosphoribosyltransferase.

Original language	English
Pages (from-to)	1087-1098
Number of pages	12
Journal	Expert Review of Anti-infective Therapy
Volume	7
Issue number	9
DOIs	https://doi.org/10.1586/ERI.09.93
Publication status	Published - 2009

Keywords

Plasmodium falciparum
aminopeptidases
antimalarials
aspartic proteinases
drug effects
histone deacetylase
malaria
pharmacology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1586/ERI.09.93

Cite this

@article{7d324f7d27f2409c83251bfa01f71a40,

title = "Plasmodium falciparum : new molecular targets with potential for antimalarial drug development",

abstract = "Malaria remains one of the world's most devastating infectious diseases. Drug resistance to all classes of antimalarial agents has now been observed, highlighting the need for new agents that act against novel parasite targets. The complete sequencing of the Plasmodium falciparum genome has allowed the identification of new molecular targets within the parasite that may be amenable to chemotherapeutic intervention. In this review, we investigate four possible targets for the future development of new classes of antimalarial agents. These targets include histone deacetylase, the aspartic proteases or plasmepsins, aminopeptidases and the purine salvage enzyme hypoxanthine-xanthine-guanine phosphoribosyltransferase.",

keywords = "Plasmodium falciparum, aminopeptidases, antimalarials, aspartic proteinases, drug effects, histone deacetylase, malaria, pharmacology",

author = "Gardiner, {Donald L.} and Skinner-Adams, {Tina S.} and Brown, {Christopher L.} and Andrews, {Katherine T.} and Stack, {Colin M.} and McCarthy, {James S.} and Dalton, {John P.} and Trenholme, {Katharine R.}",

year = "2009",

doi = "10.1586/ERI.09.93",

language = "English",

volume = "7",

pages = "1087--1098",

journal = "Expert Review of Anti-infective Therapy",

issn = "1744-8336",

publisher = "Taylor & Francis",

number = "9",

}

TY - JOUR

T1 - Plasmodium falciparum : new molecular targets with potential for antimalarial drug development

AU - Gardiner, Donald L.

AU - Skinner-Adams, Tina S.

AU - Brown, Christopher L.

AU - Andrews, Katherine T.

AU - Stack, Colin M.

AU - McCarthy, James S.

AU - Dalton, John P.

AU - Trenholme, Katharine R.

PY - 2009

Y1 - 2009

N2 - Malaria remains one of the world's most devastating infectious diseases. Drug resistance to all classes of antimalarial agents has now been observed, highlighting the need for new agents that act against novel parasite targets. The complete sequencing of the Plasmodium falciparum genome has allowed the identification of new molecular targets within the parasite that may be amenable to chemotherapeutic intervention. In this review, we investigate four possible targets for the future development of new classes of antimalarial agents. These targets include histone deacetylase, the aspartic proteases or plasmepsins, aminopeptidases and the purine salvage enzyme hypoxanthine-xanthine-guanine phosphoribosyltransferase.

AB - Malaria remains one of the world's most devastating infectious diseases. Drug resistance to all classes of antimalarial agents has now been observed, highlighting the need for new agents that act against novel parasite targets. The complete sequencing of the Plasmodium falciparum genome has allowed the identification of new molecular targets within the parasite that may be amenable to chemotherapeutic intervention. In this review, we investigate four possible targets for the future development of new classes of antimalarial agents. These targets include histone deacetylase, the aspartic proteases or plasmepsins, aminopeptidases and the purine salvage enzyme hypoxanthine-xanthine-guanine phosphoribosyltransferase.

KW - Plasmodium falciparum

KW - aminopeptidases

KW - antimalarials

KW - aspartic proteinases

KW - drug effects

KW - histone deacetylase

KW - malaria

KW - pharmacology

UR - http://handle.uws.edu.au:8081/1959.7/551336

U2 - 10.1586/ERI.09.93

DO - 10.1586/ERI.09.93

M3 - Article

C2 - 19883329

SN - 1744-8336

SN - 1478-7210

VL - 7

SP - 1087

EP - 1098

JO - Expert Review of Anti-infective Therapy

JF - Expert Review of Anti-infective Therapy

IS - 9

ER -

Plasmodium falciparum : new molecular targets with potential for antimalarial drug development

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this